Haemonetics (HAE) Tops Q3 EPS by 11c

Haemonetics (NYSE: HAE) reported Q3 EPS of $0.84, $0.11 better than the analyst estimate of $0.73. Revenue for the quarter came in at $260 million versus the consensus estimate of $266.94 million.

GUIDANCE:

Haemonetics sees FY2022 EPS of $2.45-$2.55, versus the consensus of $2.53.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Solstice acquiring Element Solutions in $14.5B cash and stock deal
• Middleby completes spin-off of food processing unit as Midera
• General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance